# Clinical Efficacy and Safety Evaluation of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia

> **NCT02899455** · PHASE3 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 146 (actual)

## Conditions studied

- Hypertension
- Hyperlipidemia

## Interventions

- **DRUG:** HGP0904
- **DRUG:** HGP0608
- **DRUG:** HGP0816
- **DRUG:** HGP0904 Placebo
- **DRUG:** HGP0816 Placebo

## Key facts

- **NCT ID:** NCT02899455
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 146 (ACTUAL)
- **Last updated:** 2016-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02899455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02899455, "Clinical Efficacy and Safety Evaluation of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02899455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*